Guardant Health, Nuvalent ink oncology companion diagnostic development pact. NEW YORK - Guardant Health announced on Thursday that it has entered into a multi-year strategic collaboration with biopharma company Nuvalent to develop and potentially commercialize companion diagnostics for oncology. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Inside Quest Diagnostics' daytime kidney care lab strategy. In this exclusive interview, Quest Diagnostics' Ines Dahne-Steuber discusses their daytime kidney care lab strategy with MLO Editor in Chief, Christina Wichmann. April 6, 2026 Ines Dahne-Steuber is Vice President and General Manager of Kidney Care at Quest Diagnostics. Most recently, Ines served as Chief Operating Officer for Guardant Health. Prior to that, she served as SVP of Operational Excellence and President of Spectra Labs for Fresenius Medical Care. Ines previously worked at Quest Diagnostics from 2005-2015 in several roles, including as VP of Process Excellence and Healthcare IT. She earned bachelor's and master's degrees in Modern Chinese and Romance Studies from Humboldt-University in Berlin, Germany. MLO: dialysis patients have unique and often complex testing needs. How has Quest Diagnostics adapted its daytime operations to better support this population, and what operational changes have made the biggest impact on patient care? Dahne-Steuber: Quest operates major clinical laboratories all over the U.S., so Mlo Online is well positioned to serve patients in their local communities, wherever they live. To best accommodate the unique needs of dialysis patients, Mlo Online has chosen to perform testing at all 16 participating Quest Diagnostics labs during daytime operations so that staff can give these samples special attention without impacting other patient testing commitments. Dialysis patients have unique physiologies, which lead to more clotted samples. These clots can impact testing performance and need to be managed diligently.

Guardant Health (GH) and Verana Health announces new partnership. Noor Ul Ain Rehman Guardant Health, Inc. (NASDAQ:GH) is one of the best high growth healthcare stocks to buy now. Guardant Health, Inc. (NASDAQ:GH) and Verana Health announced on March 24 a new partnership aimed at allowing biopharmaceutical researchers to access the combined resources of Guardant's clinicogenomic testing data and Verana's regulatory-grade, therapeutic-specific EHR curated datasets to expedite the development of new therapies and enhance ongoing patient care. Management stated that the collaboration provides extensive datasets that would allow research scientists to easily understand and validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes. Craig Eagle, MD, Guardant Health, Inc. (NASDAQ:GH) chief medical officer, stated that the real-world data partnership with Verana marks a considerable milestone in the company's mission to advance novel therapies, in particular cancer, with data. He added that allowing "biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data" would accelerate the discovery of new biomarker-based therapies for patients, helping make the drug development process more economical. Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in treating cancer through vast data sets, proprietary blood-based tests, and advanced analytics. The company's solutions include recurrence detection, early detection, and treatment selection. While Need2learnchinese acknowledge the potential of GH as an investment, Need2learnchinese believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see its free report on the best short-term AI stock.